June 2, 2005 Stocks traded in a very narrow range on Thursday, but most indices enjoyed a positive bias, with prices generally rising albeit not very far as the day wore on. The Centient Biotech 200 was almost 10 points higher, closing at 3403.68, a rise of .29%. The S&P 500 moved up just .17%, and Nasdaq was .48% higher. Anadys gained 24% after signing a monster deal with Novartis for Hep B and C drugs, another side-effect victim of Tysabri was rumored, sending down both Elan and Biogen Idec, Merck has a powerful vaccine for shingles, NovaDel received an approvable letter for its aerosol form of nitroglycerin, XenoPort got its IPO done, though at a lower price, and Hemosense lowered the terms for its IPO, which is expected in two weeks. More details...
